Literature DB >> 15726541

Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection.

Simona Urbani1, Carolina Boni, Barbara Amadei, Paola Fisicaro, Simona Cerioni, Maria Antonietta Valli, Gabriele Missale, Carlo Ferrari.   

Abstract

To characterize acute-phase hepatitis B virus (HBV)-specific T cell responses associated with self-limited and persistent HBV infections, we compared a patient with acute HBV/HCV coinfection, who was able to control HCV but developed chronic hepatitis B, with patients who resolved acute HBV infection spontaneously. Acute-phase CD4 responses were efficient in self-limited infections but undetectable in the coinfected patient with HBV persistence. CD8 responses were multispecific irrespective of the outcome of infection, but the CD8 repertoire associated with HBV persistence lacked the most dominant specificities detectable in self-limited infections. In conclusion, insufficient CD4 help and defective CD8 repertoire may play a role at the early stages of infection in influencing HBV persistence.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15726541     DOI: 10.1002/hep.20614

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  28 in total

Review 1.  Gut microbiota modulate the immune effect against hepatitis B virus infection.

Authors:  D Xu; Y Huang; J Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-08-14       Impact factor: 3.267

Review 2.  Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells.

Authors:  Barbara Rehermann
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

3.  Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection.

Authors:  Xiaoming Cheng; Takuro Uchida; Yuchen Xia; Regina Umarova; Chun-Jen Liu; Pei-Jer Chen; Anuj Gaggar; Vithika Suri; Marcus M Mücke; Johannes Vermehren; Stefan Zeuzem; Yuji Teraoka; Mitsutaka Osawa; Hiroshi Aikata; Keiji Tsuji; Nami Mori; Shuhei Hige; Yoshiyasu Karino; Michio Imamura; Kazuaki Chayama; T Jake Liang
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

Review 4.  Acute exacerbation of chronic hepatitis B: the dilemma of differentiation from acute viral hepatitis B.

Authors:  Pankaj Puri
Journal:  J Clin Exp Hepatol       Date:  2013-10-17

5.  Interleukin-21 gene polymorphisms and chronic hepatitis B infection in a Chinese population.

Authors:  Jia-Yan Yao; Kang Chao; Min-Rui Li; Yan-Qing Wu; Bi-Hui Zhong
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

6.  A global scientific strategy to cure hepatitis B.

Authors:  Peter A Revill; Francis V Chisari; Joan M Block; Maura Dandri; Adam J Gehring; Haitao Guo; Jianming Hu; Anna Kramvis; Pietro Lampertico; Harry L A Janssen; Massimo Levrero; Wenhui Li; T Jake Liang; Seng-Gee Lim; Fengmin Lu; M Capucine Penicaud; John E Tavis; Robert Thimme; Fabien Zoulim
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-04-10

7.  Cytotoxic T lymphocytes and CD4 epitope mutations in the pre-core/core region of hepatitis B virus in chronic hepatitis B carriers in Northeast Iran.

Authors:  Sareh Zhand; Alijan Tabarraei; Amineh Nazari; Abdolvahab Moradi
Journal:  Indian J Gastroenterol       Date:  2017-07-25

Review 8.  Hepatitis B virus and hepatitis C virus dual infection.

Authors:  Gaia Caccamo; Francesca Saffioti; Giovanni Raimondo
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

9.  T Cell Distribution in Relation to HIV/HBV/HCV Coinfections and Intravenous Drug Use.

Authors:  Eveli Kallas; Kristi Huik; Silver Türk; Merit Pauskar; Ene-Ly Jõgeda; Marina Šunina; Tõnis Karki; Don Des Jarlais; Anneli Uusküla; Radko Avi; Irja Lutsar
Journal:  Viral Immunol       Date:  2016-08-26       Impact factor: 2.257

10.  A novel model of acute liver injury in mice induced by T cell-mediated immune response to lactosylated bovine serum albumin.

Authors:  Ling Xu; Ying Zhao; Yu Qin; Qiang Xu
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.